

September 5, 2017



## Veru Inc. to Participate in Upcoming Financial Conferences

MIAMI, Sept. 05, 2017 (GLOBE NEWSWIRE) -- Veru Inc. (Nasdaq:VERU) (formerly, Nasdaq:FHCO) ("Veru" or the "company"), a biopharmaceutical company focused on urology and oncology, today announces that it will participate in two upcoming financial conferences.



- Rodman & Renshaw's 19<sup>th</sup> Annual Global Investment Conference – Presenting on September 12, 4:40 PM ET, Louis Room, Lotte New York Palace Hotel, New York City. Live audio webcast of the presentation will be available under the [investor relations](#) section of Veru's website at [www.veruhealthcare.com](http://www.veruhealthcare.com). Replays of the presentations will be available for 30 days following the events also at [www.veruhealthcare.com](http://www.veruhealthcare.com).
- Morgan Stanley Healthcare Conference 2017 – The company will host one-on-one meetings on September 12-13, Grand Hyatt Hotel, New York City.

### About Veru Inc.

Veru Inc. (Veru) is a biopharmaceutical company focused on urology and oncology. Veru utilizes FDA's 505(b)(2) regulatory approval pathway to develop and commercialize drug candidates. FDA's 505(b)(2) regulatory approval pathway is designed to allow for potentially expedited regulatory approval based on a previously established safety and efficacy profile of the product. Veru is developing products under the 505(b)(1) pathway as well, which is the

traditional new drug application (NDA) pathway. The company is currently developing drug product candidates for benign prostatic hyperplasia (BPH or enlarged prostate), hot flashes associated with prostate cancer hormone treatment, male infertility and novel oral chemotherapy (alpha & beta tubulin inhibitor) for a variety of malignancies, including metastatic prostate, breast and ovarian cancers. In addition, the company markets and sells the FC2 Female Condom<sup>®</sup> (now available by prescription in the US) and PREBOOST<sup>®</sup> medicated individual wipe, which is a male genital desensitizing drug product for the prevention of premature ejaculation.

The company's division, The Female Health Company, is focused on the global public health sector FC2 business. This division markets the company's Female Condom (FC2) to entities, including ministries of health, government health agencies, U.N. agencies, nonprofit organizations and commercial partners, that work to support and improve the lives, health and well-being of women around the world.

More information about Veru and its products can be found at [www.veruhealthcare.com](http://www.veruhealthcare.com), [www.PREBOOST.com](http://www.PREBOOST.com) and [www.fc2femalecondom.com](http://www.fc2femalecondom.com). For corporate and investor-related information about the Company, please visit <https://veruhealthcare.com/investors>.

**"Safe Harbor" statement under the Private Securities Litigation Reform Act of 1995:**

*The statements in this release that are not historical fact are "forward-looking statements" as that term is defined in the Private Securities Litigation Reform Act of 1995. Any forward-looking statements in this release are based upon the Company's current plans and strategies, and reflect the Company's current assessment of the risks and uncertainties related to its business, and are made as of the date of this release. The Company assumes no obligation to update any forward-looking statements contained in this release as a result of new information or future events, developments or circumstances. Such forward-looking statements are inherently subject to known and unknown risks and uncertainties. The Company's actual results and future developments could differ materially from the results or developments expressed in, or implied by, these forward-looking statements. Factors that may cause actual results to differ materially from those contemplated by such forward-looking statements include, but are not limited to, the following: product demand and market acceptance; competition in the Company's markets and the risk of new competitors and new competitive product introductions; risks relating to the ability of the Company to obtain sufficient financing on acceptable terms when needed to fund development and operations; risks related to the development of the Company's product portfolio, including clinical trials, regulatory approvals and time and cost to bring to market; many of the Company's products are at an early stage of development and the Company may fail to successfully commercialize such products; risks related to intellectual property, including licensing risks; government contracting risks, including the appropriations process and funding priorities, potential bureaucratic delays in awarding contracts, process errors, politics or other pressures, and the risk that government tenders and contracts may be subject to cancellation, delay or restructuring; a governmental tender award indicates acceptance of the bidder's price rather than an order or guarantee of the purchase of any minimum number of units, and as a result government ministries or other public sector customers may order and purchase fewer units than the full maximum tender amount; the Company's reliance on its international partners in the consumer sector and on the level of spending on the female condom by country governments, global donors and other public health organizations in the global public sector; the economic and business environment and the impact of government*

*pressures; risks involved in doing business on an international level, including currency risks, regulatory requirements, political risks, export restrictions and other trade barriers; the Company's production capacity, efficiency and supply constraints; risks related to the costs and other effects of litigation; the Company's ability to identify, successfully negotiate and complete suitable acquisitions or other strategic initiatives; the Company's ability to successfully integrate acquired businesses, technologies or products; and other risks detailed in the Company's press releases, shareholder communications and Securities and Exchange Commission filings, including the Company's Form 10-K for the year ended September 30, 2016. These documents are available on the "SEC Filings" section of our website at [www.veruhealthcare.com/investors](http://www.veruhealthcare.com/investors).*

Contact:

Kevin Gilbert

Veru Inc.

786-322-2213

KGilbert@veruhealthcare.com

Jules Abraham

JQA Partners, Inc.

917-885-7378

jabraham@jqapartners.com

Source: Veru Inc.